New KIM-1 ELISA Kit from Enzo Life Sciences, Inc.

New KIM-1 ELISA Kit from Enzo Life Sciences, Inc. is Most Sensitive for Quantifying Biomarker of Early Stage Kidney Injury and Disease. Strengthening its position as an innovator in tools for detection of acute kidney injury (AKI), diabetes, and toxicity, Enzo now offers the most sensitive KIM-1 (human) ELISA Kit.

Written byEnzo Life Sciences, Inc.
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

New KIM-1 ELISA Kit from Enzo Life Sciences, Inc. is Most Sensitive for Quantifying Biomarker of Early Stage Kidney Injury and Disease. Strengthening its position as an innovator in tools for detection of acute kidney injury (AKI), diabetes, and toxicity, Enzo now offers the most sensitive KIM-1 (human) ELISA Kit.

KIM-1, also known as kidney injury marker 1 or TIM-1, is the most highly upregulated protein in the proximal tubule of the injured kidney and is detectable in the urine within 6 hours of injury. KIM-1 has been identified as an early diagnostic and prognostic marker of AKI resulting from illness, trauma, or nephrotoxicity, and with decreased kidney function and renal failure associated with chronic disorders such as diabetes and high blood pressure.

This quantitative ELISA kit offers ultra-sensitive detection enabling quantification of both normal and disease state levels of KIM-1, detecting as little as 1.2 pg/mL of KIM-1 in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo